HemoSense was acquired by Inverness Medical Innovations in November 2007. Please visit the Inverness Medical Corporate website for Investor information.

HemoSense develops, manufactures and sells easy-to-use, handheld blood coagulation monitoring systems for use by patients and healthcare professionals in the management of warfarin medication. Warfarin is an oral anticoagulant, or blood thinning, drug given to patients to prevent potentially lethal blood clots.

Our product, the INRatio System, consists of a small, portable meter and disposable test strips and provides a quick and accurate measurement of a patient's blood clotting time, known as a PT/INR value. The accurate measurement of the PT/INR value is critical to ensuring the safety and effectiveness of warfarin in maintaining a patient’s blood coagulation level within a therapeutic range.

We commercially launched the INRatio System in March 2003 in the United States and certain European markets. Tests performed using our INRatio System in the point-of-care setting are currently reimbursed by Medicare for all patients on warfarin as is self-testing for atrial fibrillation, deep vein thrombosis, venous thromboembolism, and mechanical heart valve patients on warfarin.